Ipsen and Its Partner Exelixis Announce Positive Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Presented at the European Soc

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. MU
3. FDX
4. SPY
5. NVDA
6. META
7. ABBV
8. ACN
9. BLZE
10. IBM

Go back to Ipsen and Its Partner Exelixis Announce Positive Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Presented at the European Soc

Leerink Bumps PT on Exelixis (EXEL) Up to $16 Following Latest Cabozantinib Data

October 11, 2016 6:27 AM EDT

Leerink is boosting its price target on Outperform-rated Exelixis (Nasdaq: EXEL) from $15 to $16 after Exelixis announced detailed results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with previously untreated advanced renal cell carcinoma (RCC) with intermediate- or poor-risk disease per the International Metastatic Renal Cell... More

Piper Jaffray Upgrades Exelixis (EXEL) to Overweight

October 10, 2016 9:09 AM EDT

Piper Jaffray upgraded Exelixis (NASDAQ: EXEL) from Neutral to Overweight.

For an analyst ratings summary and ratings history on Exelixis click here. For more ratings news on Exelixis click here.

Shares of Exelixis closed at $12.95 yesterday.

... More

Exelixis (EXEL) Bullish View Reiterated at Leerink Following Positive CABOSUN Data

October 10, 2016 7:40 AM EDT

Leerink Partners analyst Michael Schmidt reiterated an Outperform rating and $15 price target on Exelixis (NASDAQ: EXEL) after the company reported positive CABOSUN data to be presented as a late breaker at ESMO later today.

Schmidt commented, "Overall, the data looks clearly statistically... More